Keep an eye on Moderna Inc. (MRNA).
The COVID-19 vaccine stock is regaining some lost ground. All after CEO Stephane Bancel said the U.S. government could authorize emergency use of the company’s vaccine by December. That is, if the company can produce positive interim results in November from its clinical trial.
According to The Wall Street Journal:
The company must “monitor the safety of at least half of the study subjects for two months after vaccination before it can seek an authorization for emergency use. Moderna was likely to reach that threshold in late November. If Moderna files for an emergency use authorization soon after, the Food and Drug Administration may take a few weeks to review the application before deciding in December.”
However, if the trials do not demonstrate sufficient efficacy during the first interim analysis, the company will conduct a second analysis “when 106 cases of symptomatic Covid-19 occur. Mr. Bancel said that would likely happen in December, which could push back any FDA decision to late January or early February.”
